HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RIFM increases transparency

This article was originally published in The Rose Sheet

Executive Summary

The Research Institute for Fragrance Materials is opening its Expert Panel review process to the public "in alignment with the fragrance industry's move towards greater transparency about its ingredients," says the scientific arm of the International Fragrance Association April 2. The move should "emphasize the credibility of its scientific methodology," according to the release. In an effort to enhance dialogue in the fragrance community, the organization is requesting information on fragrance materials in advance of meetings. The panel expects to next meet in early May to discuss macrocyclic lactones and lactides, macrocyclic ketones and ketones cyclopentanone and cyclopentenone. Information on the compounds will be accepted through April 16 and compiled as background to inform panel's discussion, RIFM says. Requests to personally present information at the meeting also will be considered

You may also be interested in...



In Brief

Council Video Squashes Cosmetic Rumors

Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.

UsernamePublicRestriction

Register

RS016840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel